Skip to main content Skip to footer

Updated endorsement guidance for SSP products

Pharmacy contractors should note that endorsement requirements for products supplied in accordance with a Serious Shortage Protocol (SSP) have been updated, as per Clause 9E, Part II of the June 2021 Drug Tariff.

The update will affect all future SSPs as well as the following SSPs which are currently in effect:

  • SSP05, fluoxetine 10mg tablets
  • SSP007, fluoxetine 30mg capsules
  • SSP012, Estradot® 75 microgram patches

Contractors should note the updated endorsement guidance when supplying in accordance with these SSPs. Also note that for endorsement purposes, SSP05 should be endorsed as SSP005.